Inventor

BEAUSOLEIL ANNE-MARIE

US32 patents

⚠️ This page may combine multiple inventors who share the name “BEAUSOLEIL ANNE-MARIE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BEAUSOLEIL ANNE-MARIE

THERAVANCE BIOPHARMA R&D IP LLC

JAK kinase inhibitor compounds for treatment of respiratory disease

JAK kinase inhibitor compounds for treatment of respiratory disease

Pyrimidine compounds as JAK kinase inhibitors

Substituted naphthyridines as JAK kinase inhibitors

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

(2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

JAK kinase inhibitor compounds for treatment of respiratory disease

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

Pyrimidine compounds as JAK kinase inhibitors

3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor

JAK kinase inhibitor compounds for treatment of respiratory disease

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid

(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acid

(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid

Neprilysin inhibitors

UNITY BIOTECHNOLOGY INC

Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer

Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer

Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer

Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer

Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer

Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer

Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer

CORVUS PHARMACEUTICALS INC

Compounds and methods for modulating bruton&#39;s tyrosine kinase

Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

Compounds and methods for modulating interleukin-2-inducible t-cell kinase

NEUMORA THERAPEUTICS INC

Methods of treating neurological disorders

Methods of treating neurological disorders

ANGEL PHARMACEUTICAL CO LTD

Compounds and methods for modulating Bruton&#39;s Tyrosine Kinase

UNITY BIOTECHNOLOGY

Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer

Compounds and methods for modulating bruton's tyrosine kinase

Compounds and methods for modulating Bruton's Tyrosine Kinase